Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Huang J, Linares JF, Duran A, Xia W, Saltiel AR, Müller TD, et al. NBR1 is a critical step in the repression of thermogenesis of p62-deficient adipocytes through PPARγ. Nat Commun. 2021;12(1):2876.

Kim D, Alperstein SA, Siddiqui MT. Standardizing a volume benchmark for cerebrospinal fluids for optimal diagnostic accuracy. Diagn Cytopathol. 2021;49(2):258-266.

Ma L, Zhao Z, Racine-Brzostek SE, Yang HS. A rare case of persistent pseudohypobicarbonatemia arising from chemistry analyzer-specific interference. Clin Chim Acta. 2021;519:308-310.

Crane GM, Liu Y-, Chadburn A. Spleen: Development, anatomy and reactive lymphoid proliferations. Semin Diagn Pathol. 2021;38(2):112-124.

Hissong E, Chiu K, Park H, Solomon J, Song W, Jessurun J. Thyroid-Like Cholangiocarcinoma: Histopathological, Immunohistochemical, In-Situ Hybridization and Molecular Studies on an Uncommon Emerging Entity. Int J Surg Pathol. 2021:10668969211013906.

Tameni A, Sauta E, Mularoni V, Torricelli F, Manzotti G, Inghirami G, et al. The DNA-helicase HELLS drives ALK ALCL proliferation by the transcriptional control of a cytokinesis-related program. Cell Death Dis. 2021;12(1):130.

Yantiss RK, Qin L, He B, Crawford CV, Seshan S, Patel S, et al. Intestinal Abnormalities in Patients With SARS-CoV-2 Infection: Histopathologic Changes Reflect Mechanisms of Disease. Am J Surg Pathol. 2021.

Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, et al. G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662.

Wang Y, Yan F, Nasar A, Chen Z-, Altorki NK, Stiles B, et al. CUL4 Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival. Am J Pathol. 2021;191(9):1638-1650.

Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, et al. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021;4(7):e2116536.